Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2019 Earnings Presentation
11 slides from Alkem Laboratories's earnings presentation, Aug 10, 2018
Slide 1: Investor Presentation Q1FY19 – August 10, 2018
Investor Presentation Q1FY19 – August 10, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q1FY19
Key Highlights of Q1FY19 A positive start to the financial year 2019 • India Business: In Q1FY19, India sales grew by 25.7% YoY. Adjusting for the change in distribution policy, the growth was even higher. India sales were impacted in Q1FY18 on account of GST rollout • The Company outperformed the I
Slide 4: Key Financial Highlights – Q1FY19 (Consolidated)
Key Financial Highlights – Q1FY19 (Consolidated) All figures in Rs mn Revenue from Operations India sales Adjusting for 10,906 the change 16,695 8,675 in distribution policy, YoY growth in Q1FY19 was 13,125 even higher Q1FY18 Q1FY19 International sales 5,479 4,057 Q1FY18 Q1FY19 Notes: Post implement
Slide 5: Key Financial Highlights – Q1FY19 (Consolidated)
Key Financial Highlights – Q1FY19 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin Adjusting for the change in 10,034 2,142 distribution policy, EBITDA 7,502 margin in Q1FY19 was higher than 944 12.8% 57.2% 60.1% 7.2% 12.8% Q1FY18 Q1FY19 Q1FY18 Q1FY19 PBT (b
Slide 6: India Business
India Business India Business: Q1FY19 Sales of Rs.10,906 million (25.7% growth YoY) • India sales contributed 66.6% to total sales in Q1FY19 • Adjusting for the change in distribution policy, YoY growth during the quarter was even higher • The Company has added about 2,000 MRs in the last two years
Slide 7: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across all the major therapeutic areas in Q1FY19 Established therapeutic +1 Market rank 1 3 3 4 areas of Alkem 15.2% 16.1% 16.4% 11.7% 8.3% 7.6% 6.5% 3.9% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alk
Slide 8: US Business
US Business US Business: Q1FY19 Sales of Rs.4,237 million (43.1% growth YoY) • US sales contributed 25.9% to total sales in Q1FY19 • Growth in the US business was driven by combination of new product launches and market share gains in the existing products • In Q1FY19, the Company filed 4 ANDAs with
Slide 9: Other International Business
Other International Business Other International Business: Q1FY19 Sales of Rs.1,242 million (13.4% growth YoY) • Other International Market sales contributed 7.6% to total sales in Q1FY19 • Company’s key markets including Australia and Chile recorded healthy growth for the quarter ending June 30, 20
Slide 10: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on June 30, 2018 Non-Institution, 27.28% Promoter & Promoter Group, Institution, 65.92% 6.80% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodies
Slide 11: Thank You
ot. \ Thank You